Volastra
Samuel Bakhoum is currently an Assistant Member (Professor) in the Human Oncology and Pathogenesis Program and the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center (MSKCC). His laboratory focuses on understanding the consequences of chromosomal instability on tumor evolution, centering on cancer metastasis and tumor-immune interaction. Samuel obtained his M.D., Ph.D. at Dartmouth Medical School. His graduate research focused on understanding the basic mechanisms of chromosome segregation during cell division. He subsequently completed an internship at Mount Auburn Hospital of Harvard Medical School and residency training in Radiation Oncology at MSKCC. While a resident, he conducted research under the mentorship of Professor Lewis Cantley at Weill Cornell Medicine, focusing on the role of chromosomal instability in tumor metastasis and the generation of a cytosolic DNA response.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Volastra
1 followers
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.